New PARP Inhibitor Approved for Breast Cancer
The FDA approved a targeted therapeutic for treating patients with breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutations.
Progress Against Cancer
The FDA approved a targeted therapeutic for treating patients with breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutations.
The FDA approved a molecularly targeted therapeutic for treating certain patients with non-small cell lung cancer.
The FDA approved a new molecularly targeted therapeutic called for treating certain patients with blood cancer.
The FDA approved a new immunotherapeutic for treating patients with a type of skin cancer called cutaneous squamous cell carcinoma.
The FDA expanded the use of nivolumab to include treating certain patients with small cell lung cancer.
The FDA approved a new molecularly targeted therapeutic for treating certain patients with a rare form of leukemia called hairy cell leukemia.
The FDA expanded the use of a molecularly targeted therapeutic to treat patients with the most common type of liver cancer, hepatocellular carcinoma.
The FDA approved a combination of a molecularly targeted therapeutic and an immunotherapy for treating patients with Waldenström's macroglobulinemia.
The FDA approved a targeted radiotherapeutic for treating certain patients with two types of neuroendocrine tumors.
The FDA approved a new immunotherapeutic for treating certain patients with two rare types of non-Hodgkin lymphoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More